Understanding anti-tuberculosis drug efficacy: Rethinking bacterial populations and how we model them

International Journal of Infectious Diseases

Volumn 32, Issue , 2015, Pages 76-80

  Evangelopoulos, Dimitrios ^a   Fonseca, Joana Diniz da ^a   Waddell, Simon J ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Drug discovery; Mycobacterium tuberculosis; Persistence models; Phenotypic drug tolerance; Subpopulations

Indexed keywords

CLOTRIMAZOLE; ECONAZOLE; ETHAMBUTOL; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; METRONIDAZOLE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CHEMOTHERAPY; DRUG EFFICACY; DRUG PENETRATION; HOST PATHOGEN INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; REVIEW; TUBERCULOSIS; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; MICROBIOLOGY;

ANIMALS; ANTITUBERCULAR AGENTS; HUMANS; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84925247870     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.11.028     Document Type: Review

References (88)

1. Sturgill-Koszycki S., Schlesinger P.H., Chakraborty P., Haddix P.L., Collins H.L., Fok A.K., et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994, 263:678-681.
2. Barry C.E., Boshoff H.I., Dartois V., Dick T., Ehrt S., Flynn J., et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7:845-855.
3. Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Micro 2014, 12:159-167.
4. Dannenberg A.M. Liquefaction and cavity formation in pulmonary TB: A simple method in rabbit skin to test inhibitors. Tuberculosis 2009, 89:243-247.
5. Kaplan G., Post F., Moreira A., Wainwright H., Kreiswirth B., Tanverdi M., et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 2003, 71:7099-7108.
6. Bothamley G., Lipman M., Kon O.M. Cavitating pulmonary tuberculosis: a global challenge. Clin Med 2012, 12:299.
7. Yoder, A.M., Lamichhane G., Bishai R.W., Cavitary pulmonary tuberculosis: The Holy Grail of disease transmission. Bangalore, INDE: Current Science Association; 2004.
8. Carret G., Flandrois J.P., Lobry J.R. Biphasic kinetics of bacterial killing by quinolones. J Antimicrob Chemother 1991, 27:319-327.
9. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10. quiz 11-2.
10. Craig W.A., Ebert S.C. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl 1990, 74:63-70.
11. Firsov A.A., Vostrov S.N., Kononenko O.V., Zinner S.H., Portnoy Y.A. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother 1999, 43:498-502.
12. Firsov A.A., Vostrov S.N., Shevchenko A.A., Zinner S.H., Cornaglia G., Portnoy Y.A., et al. MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model. Antimicrob Agents Chemother 1998, 42:2848-2852.
13. Fung-Tomc J.C., Gradelski E., Valera L., Kolek B., Bonner D.P. Comparative killing rates of fluoroquinolones and cell wall-active agents. Antimicrob Agents Chemother 2000, 44:1377-1380.
14. Regoes R.R., Wiuff C., Zappala R.M., Garner K.N., Baquero F., Levin B.R., et al. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother 2004, 48:3670-3676.
15. Wallis R.S., Palaci M., Eisenach K. Persistence, not resistance, is the cause of loss of isoniazid effect. J Infect Dis 2007, 195:1870-1871. author reply 1872-3.
16. Wallis R.S., Patil S., Cheon S.H., Edmonds K., Phillips M., Perkins M.D., et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999, 43:2600-2606.
17. Mitchison D.A., Jindani A., Davies G.R., Sirgel F. Isoniazid activity is terminated by bacterial persistence. J Infect Dis 2007, 195:1871-1872. author reply 1872-3.
18. Gomez J.E., McKinney J.D. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004, 84:29-44.
19. Dick T. Dormant tubercle bacilli: the key to more effective TB chemotherapy?. J Antimicrob Chemother 2001, 47:117-118.
20. Warner D., Mizrahi V. Tuberculosis Chemotherapy: the Influence of Bacillary Stress and Damage Response Pathways on Drug Efficacy. Clin Microbiol Rev 2006, 19:558-570.
21. Roupie V., Romano M., Zhang L., Korf H., Lin M.Y., Franken K.L., et al. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun 2007, 75:941-949.
22. Wayne L.G., Hayes L.G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996, 64:2062-2069.
23. Wayne L.G., Sramek H.A. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994, 38:2054-2058.
24. Tudo G., Laing K., Mitchison D.A., Butcher P.D., Waddell S.J. Examining the basis of isoniazid tolerance in nonreplicating Mycobacterium tuberculosis using transcriptional profiling. Future Med Chem 2010, 2:1371-1383.
25. Boshoff H.I., Barry C.E. Tuberculosis - metabolism and respiration in the absence of growth. Nat Rev Microbiol 2005, 3:70-80.
26. Hingley-Wilson S.M., Sambandamurthy V.K., Jacobs W.R. Survival perspectives from the world's most successful pathogen. Mycobacterium tuberculosis. Nat Immunol 2003, 4:949-955.
27. Garton N.J., Waddell S.J., Sherratt A.L., Lee S.M., Smith R.J., et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 2008, 5:e75.
28. Boshoff H., Barry C. Tuberculosis - metabolism and respiration in the absence of growth. Nat Rev Microbiol 2005, 3:70-80.
29. Boon C., Dick T. Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J Bacteriol 2002, 184:6760-6767.
30. Voskuil M., Schnappinger D., Visconti K., Harrell M., Dolganov G., Sherman D., et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 2003, 198:705-713.
31. Voskuil M., Visconti K., Schoolnik G. Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis (Edinb) 2004, 84:218-227.
32. Mitchison D.A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985, 66:219-225.
33. Mitchison D.A., Coates A.R. Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs. Curr Pharm Des 2004, 10:3285-3295.
34. Wayne L., Hayes L. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996, 64:2062-2069.
35. Wayne L., Sohaskey C. Nonreplicating persistence of mycobacterium tuberculosis. Annu Rev Microbiol 2001, 55:139-163.
36. Cressy N.L. The Tubercle Bacillus in the Pulmonary Lesion of Man. The Yale journal of biology and medicine 1955, 28:72.
37. Khan A., Sarkar D. A simple whole cell based high throughput screening protocol using Mycobacterium bovis BCG for inhibitors against dormant and active tubercle bacilli. J Microbiol Methods 2008, 73:62-68.
38. Wayne L., Sramek H. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994, 38:2054-2058.
39. Wayne L. Synchronized replication of Mycobacterium tuberculosis. Infect Immun 1977, 17:528-530.
40. Hu Y., Butcher P., Sole K., Mitchison D., Coates A. Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol Lett 1998, 158:139-145.
41. Lenaerts A.J., Gruppo V., Marietta K.S., Johnson C.M., Driscoll D.K., Tompkins N.M., et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005, 49:2294-2301.
42. Cho S.H., Warit S., Wan B., Hwang C.H., Pauli G.F., Franzblau S.G. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007, 51:1380-1385.
43. Taneja N.K., Tyagi J.S. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. J Antimicrob Chemother 2007, 60:288-293.
44. Galagan J.E., Minch K., Peterson M., Lyubetskaya A., Azizi E., Sweet L., et al. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature 2013, 499:178-183.
45. Betts J.C., Lukey P.T., Robb L.C., McAdam R.A., Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Molecular Microbiology 2002, 43:717-731.
46. Murphy D.J., Brown J.R. Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. BMC Infect Dis 2007, 7:84.
47. Archuleta R.J., Yvonne Hoppes P., Primm T.P. Mycobacterium avium enters a state of metabolic dormancy in response to starvation. Tuberculosis (Edinb) 2005, 85:147-158.
48. Phyu S., Mustafa T., Hofstad T., Nilsen R., Fosse R., Bjune G. A mouse model for latent tuberculosis. Scand J Infect Dis 1998, 30:59-68.
49. Ahmad Z., Sharma S., Khuller G.K. The potential of azole antifungals against latent/persistent tuberculosis. FEMS Microbiol Lett 2006, 258:200-203.
50. Hampshire T., Soneji S., Bacon J., James B.W., Hinds J., Laing K., et al. Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: a model for persistent organisms?. Tuberculosis (Edinb) 2004, 84:228-238.
51. Bacon J., James B.W., Wernisch L., Williams A., Morley K.A., Hatch G.J., et al. The influence of reduced oxygen availability on pathogenicity and gene expression in Mycobacterium tuberculosis. Tuberculosis (Edinb) 2004, 84:205-217.
52. Beste D.J.V., Espasa M., Bonde B., Kierzek A.M., Stewart G.R., McFadden J. The Genetic Requirements for Fast and Slow Growth in Mycobacteria. PLoS ONE 2009, 4:e5349.
53. Salina E.G., Waddell S.J., Hoffmann N., Rosenkrands I., Butcher P.D., Kaprelyants A.S. Potassium availability triggers Mycobacterium tuberculosis transition to, and resuscitation from, non-culturable (dormant) states. Open Biol 2014, 4.
54. Golby P., Hatch K.A., Bacon J., Cooney R., Riley P., Allnutt J. Comparative transcriptomics reveals key gene expression differences between the human and bovine pathogens of the Mycobacterium tuberculosis complex. Microbiology 2007, 153:3323-3336.
55. Fisher M.A., Plikaytis B.B., Shinnick T.M. Microarray analysis of the Mycobacterium tuberculosis transcriptional response to the acidic conditions found in phagosomes. J Bacteriol 2002, 184:4025-4032.
56. Deb C., Lee C.M., Dubey V.S., Daniel J., Abomoelak B., Sirakova T.D. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One 2009, 4:e6077.
57. Ojha A.K., Baughn A.D., Sambandan D., Hsu T., Trivelli X., Guerardel Y., et al. Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Molecular Microbiology 2008, 69:164-174.
58. Wakamoto Y., Dhar N., Chait R., Schneider K., Signorino-Gelo F., Leibler S., et al. Dynamic Persistence of Antibiotic-Stressed Mycobacteria. Science 2013, 339:91-95.
59. Hol F.J.H., Dekker C. Zooming in to see the bigger picture: Microfluidic and nanofabrication tools to study bacteria. Science 2014, 346.
60. Murphy D., Brown J. Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. BMC Infectious Diseases 2007, 7:84.
61. Dhillon J., Andries K., Phillips P.P., Mitchison D.A. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis (Edinb) 2010, 90:301-305.
62. Christophe T., Jackson M., Jeon H.K., Fenistein D., Contreras-Dominguez M., Kim J., et al. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog 2009, 5:e1000645.
63. Schnappinger D., Ehrt S., Voskuil M.I., Liu Y., Mangan J.A., Monahan I.M., et al. Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. J Exp Med 2003, 198:693-704.
64. Tailleux L., Waddell S.J., Pelizzola M., Mortellaro A., Withers M., Tanne A., et al. Probing host pathogen cross-talk by transcriptional profiling of both Mycobacterium tuberculosis and infected human dendritic cells and macrophages. PLoS One 2008, 3:e1403.
65. Rohde K.H., Veiga D.F., Caldwell S., Balazsi G., Russell D.G. Linking the transcriptional profiles and the physiological states of Mycobacterium tuberculosis during an extended intracellular infection. PLoS Pathog 2012, 8:e1002769.
66. Waddell S.J. Reprogramming the Mycobacterium tuberculosis transcriptome during pathogenesis. Drug Discovery Today: Disease Mechanisms 2010, 7:e67-e73.
67. Fitzgerald L.E., Abendano N., Juste R.A., Alonso-Hearn M. Three-dimensional in vitro models of granuloma to study bacteria-host interactions, drug-susceptibility, and resuscitation of dormant mycobacteria. Biomed Res Int 2014, 2014:623856.
68. Daniel J., Maamar H., Deb C., Sirakova T.D., Kolattukudy P.E. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog 2011, 7:e1002093.
69. Puissegur M.P., Botanch C., Duteyrat J.L., Delsol G., Caratero C., Altare F. An in vitro dual model of mycobacterial granulomas to investigate the molecular interactions between mycobacteria and human host cells. Cell Microbiol 2004, 6:423-433.
70. Wang C., Peyron P., Mestre O., Kaplan G., van Soolingen D., Gao Q., et al. Innate immune response to Mycobacterium tuberculosis Beijing and other genotypes. PLoS One 2010, 5:e13594.
71. Kapoor N., Pawar S., Sirakova T.D., Deb C., Warren W.L., Kolattukudy P.E., et al. Human granuloma in vitro model, for TB dormancy and resuscitation. PLoS One 2013, 8:e53657.
72. Gupta U.D., Katoch V.M. Animal models of tuberculosis. Tuberculosis (Edinb) 2005, 85:277-293.
73. Young D. Animal models of tuberculosis. European Journal of Immunology 2009, 39:2011-2014.
74. Flynn J.L., Scanga C.A., Tanaka K.E., Chan J. Effects of aminoguanidine on latent murine tuberculosis. J Immunol 1998, 160:1796-1803.
75. Scanga C.A., Mohan V.P., Joseph H., Yu K., Chan J., Flynn J.L., et al. Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 1999, 67:4531-4538.
76. Orme I.M. A mouse model of the recrudescence of latent tuberculosis in the elderly. Am Rev Respir Dis 1988, 137:716-718.
77. Lowrie D.B., Tascon R.E., Bonato V.L., Lima V.M., Faccioli L.H., Stavropoulos E., et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999, 400:269-271.
78. Dhillon J., Allen B.W., Hu Y.M., Coates A.R., Mitchison D.A. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis 1998, 2:736-742.
79. Rhoades E., Frank A., Orme I. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber Lung Dis 1997, 78:57-66.
80. Via L.E., Lin P.L., Ray S.M., Carrillo J., Allen S., et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 2008, 76:2333-2340.
81. Turner O.C., Basaraba R.J., Orme I.M. Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect Immun 2003, 71:864-871.
82. Lenaerts A.J., Hoff D., Aly S., Ehlers S., Andries K., Cantarero L., et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother 2007, 51:3338-3345.
83. Basaraba R.J., Bielefeldt-Ohmann H., Eschelbach E.K., Reisenhauer C., Tolnay A.E., Taraba L.C. Increased expression of host iron-binding proteins precedes iron accumulation and calcification of primary lung lesions in experimental tuberculosis in the guinea pig. Tuberculosis (Edinb) 2008, 88:69-79.
84. Dannenberg A.M. Pathogenesis of pulmonary Mycobacterium bovis infection: basic principles established by the rabbit model. Tuberculosis (Edinb.) 2001, 81:87-96.
85. McMurray D.N., Collins F.M., Dannenberg A.M., Smith D.W. Pathogenesis of experimental tuberculosis in animal models. Curr. Top. Microbiol. Immunol. 1996, 215:157-179.
86. Manabe Y.C. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb.) 2008, 88:187-196.
87. Kesavan A.K., Brooks M., Tufariello J., Chan J., Manabe Y.C. Tuberculosis genes expressed during persistence and reactivation in the resistant rabbit model. Tuberculosis (Edinb.) 2009, 89:17-21.
88. Patel K., Jhamb S.S., Singh P.P. Models of latent tuberculosis: their salient features, limitations, and development. J Lab Physicians 2011, 3:75-79.